Moderate-severe persistent allergic rhinitis
Conditions
Interventions
Control group (bilateral anterior ethmoidal neurectomy group):Endoscopic bilateral anterior ethmoidal neurectomy
Intervention group (bilateral anterior ethmoidal + sphenopalatine neurectomy group):Endoscopic bilateral anterior ethmoidal + sphenopalatine neurectomy
Sponsors
First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years, with no gender limitation; 2. Diagnosed as moderate-severe persistent allergic rhinitis in accordance with the 2022 edition of the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in China"; 3. Poor control of main symptoms, significantly affecting life after conservative treatment, and/or unable to adhere to long-term desensitization therapy; 4. Strong willingness to undergo surgery, understanding the content and purpose of the study, and signing the surgical consent form and the informed consent form for enrollment.
Exclusion criteria
Exclusion criteria: 1. With mental illness or poor compliance; 2. Poor general condition, unable to tolerate surgery; 3. Aged 70 years; 4. With bleeding tendency or coagulation dysfunction; 5. Without receiving conventional drug therapy or immunotherapy; 6. Uncontrolled asthma or in acute exacerbation; 7. Combined with nasal tumors detected by preoperative examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS nasal symptom score;RQLQ quality of life score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of substance P, NPY, periostin, IL-5 and eotaxin-2 in nasal lavage fluid;Nasal resistance and acoustic rhinometry parameters;Incidence of postoperative complications (headache, dry eye, palatal numbness, etc.);Pulmonary function;Nitric oxide; | — |
Countries
China
Contacts
Public ContactWei Hongquan
First Affiliated Hospital of China Medical University
Outcome results
None listed